Ultragenyx Pharmaceutical Inc.
Organization details
- Legal name
- Ultragenyx Pharmaceutical Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Novato
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RARE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001515673
- EIN
- 27-2546083
Board of directors
-
Amrit Ray · DirectorSince 2023
-
Corazon (Corsee) D. Sanders · DirectorSince 2023
-
Daniel G. Welch · DirectorSince 2023
-
Deborah Dunsire · DirectorSince 2023
-
Emil D. Kakkis · Director · President & CEOSince 2023
-
Matthew K. Fust · DirectorSince 2023
-
Michael Narachi · DirectorSince 2023
-
Shehnaaz Suliman · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.4%
-
90.1%
-
98.6%
Board connections
6 of this board's directors also sit on 12 other boards. 11 are in the same sector.
- via Shehnaaz Suliman
-
Atara Biotherapeutics Inc. Same sectorvia Matthew K. Fust
-
BeOne Medicines Ltd. Same sectorvia Corazon (Corsee) D. Sanders
-
Calidi Biotherapeutics Inc. Same sectorvia Corazon (Corsee) D. Sanders
-
Electra Therapeutics Inc. Same sectorvia Matthew K. Fust
-
Fortrea Holdings Inc. Same sectorvia Amrit Ray
-
Legend Biotech Corporation Same sectorvia Corazon (Corsee) D. Sanders
-
McKesson Corporation Same sectorvia Deborah Dunsire
-
Neumora Therapeutics Inc. Same sectorvia Matthew K. Fust
-
Nuvation Bio Inc. Same sectorvia Daniel G. Welch
-
Prothena Corporation plc Same sectorvia Daniel G. Welch
-
Structure Therapeutics Inc. Same sectorvia Daniel G. Welch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $3,809,849
- 28 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 15, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −7,066 | $15.27 | $107,898 |
| Sep 15, 2026 | Huizenga Theodore Alan Officer (SVP, Chief Accounting Officer) | Open-market sale | −1,283 | $13.57 | $17,410 |
| Sep 3, 2026 | Huizenga Theodore Alan Officer (SVP, Chief Accounting Officer) | Open-market sale | −161 | $13.99 | $2,252 |
| Aug 3, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −4,696 | $24.92 | $117,024 |
| Aug 3, 2026 | Karah Herdman Parschauer Officer (EVP and Chief Legal Officer) | Open-market sale | −1,900 | $24.92 | $47,348 |
| Jul 1, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −4,698 | $33.13 | $155,645 |
| Jun 15, 2026 | Corazon (Corsee) D. Sanders Director | Open-market sale | −2,000 | $25.05 | $50,100 |
| Jun 15, 2026 | Karah Herdman Parschauer Officer (EVP and Chief Legal Officer) | Open-market sale | −1,899 | $24.62 | $46,753 |
| Jun 1, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −4,653 | $23.77 | $110,602 |
| May 18, 2026 | Shehnaaz Suliman Director | Open-market sale | −5,740 | $25.12 | $144,189 |
| May 14, 2026 | Matthew K. Fust Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Shehnaaz Suliman Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Amrit Ray Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Corazon (Corsee) D. Sanders Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Michael Narachi Director | Grant or award | +7,751 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Ultragenyx Pharmaceutical Inc.
Who is the CEO of Ultragenyx Pharmaceutical Inc.?
Emil D. Kakkis is Ultragenyx Pharmaceutical Inc.'s President & CEO.
How many directors are on Ultragenyx Pharmaceutical Inc.'s board?
Ultragenyx Pharmaceutical Inc.'s board has 8 directors: Amrit Ray, Corazon (Corsee) D. Sanders, Daniel G. Welch, Deborah Dunsire, Emil D. Kakkis, Matthew K. Fust, Michael Narachi and Shehnaaz Suliman.
Are Ultragenyx Pharmaceutical Inc. insiders buying or selling shares?
Over the last 12 months, Ultragenyx Pharmaceutical Inc. insiders made no open-market purchases and sold $3.8 million of shares in 28 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="ultragenyx-pharmaceutical-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.